Korczynski Sherry 4

4 · Aquestive Therapeutics, Inc. · Filed Mar 11, 2026

AI-generated summary of this filing

Updated Mar 11, 2026

Aquestive (AQST) CCO Sherry Korczynski Sells Shares, Receives Awards

What Happened

Sherry Korczynski, Chief Commercial Officer of Aquestive Therapeutics (AQST), reported a sell-to-cover stock sale and two awards. On 2026-03-10 she disposed of 15,741 shares in open-market transactions for a weighted average price of $4.17, totaling $65,687. On 2026-03-09 she received two acquisitions: 75,000 restricted shares (reported at $0.00) and a 42,500-share derivative grant with a grant-value of $4.29 per share (total ~$182,325).

Key Details

Transaction dates and prices:
- 2026-03-09: Award of 75,000 restricted shares (reported $0.00).
- 2026-03-09: Derivative award of 42,500 shares at $4.29 (total ~$182,325).
- 2026-03-10: Open-market sale of 15,741 shares at a weighted avg $4.17 (total $65,687). Footnote: sale executed in multiple trades at $4.17–$4.32; $4.17 is the weighted average.
Shares owned after the transactions: Not disclosed in the filing.
Notable footnotes:
- F1/F4: The restricted stock and the options/derivative award vest in three annual installments (25% / 25% / 50%).
- F2: The 15,741-share sale was a mandatory "sell-to-cover" to satisfy tax withholding on vesting and was not a discretionary trade by the reporting person.
- F3: Multiple-trade execution; detailed per-trade prices available on request.
Filing timeliness: Report filed 2026-03-11 for transactions dated 2026-03-09–03-10 (appears filed within the standard Form 4 reporting window).

Context

The sale appears to be administrative (sell-to-cover for tax withholding) rather than a discretionary exit. The derivative grant and restricted shares are typical compensation awards that vest over time; the derivative grant is not an immediate exercise/sale. As always, awards and mandatory tax sales do not by themselves indicate the insider’s market view.

Form 4

Period: 2026-03-09

Chief Commercial Officer

Transactions

Award
Common Stock
[F1]
2026-03-09+75,000→ 256,858 total
Sale
Common Stock
[F2][F3]
2026-03-10$4.17/sh−15,741$65,687→ 241,117 total
Award
Non-Qualified Stock Option (right to buy)
[F4]
2026-03-09$4.29/sh+42,500$182,325→ 42,500 total
Exercise: $4.29Exp: 2036-03-09→ Common Stock (42,500 underlying)

Footnotes (4)

[F1]The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
[F2]Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
[F3]This transaction was executed in multiple trades at prices ranging from $4.17 to $4.32. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
[F4]The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Signature

/s/ Lori Braender, as Attorney-In-Fact|2026-03-11

1 file